The overall quarterly revenue for Pfizer, the world’s largest global research-based biomedical and pharmaceutical company, fell 2.4 percent to $12 billion, and third-quarter net income dropped 77%. Additionally, the company stands to lose patent protection within the next four years on drugs accounting for about half of its 2006 revenue. Key among these products is cholesterol drug Atorvastatin® (Lipitor), the world’s single most successful drug.
In addition, the discontinuation of Exubera® leaves Pfizer with one less drug to make up for those losses. While Pfizer will live to fight another day, the same cannot now be said for Exubera.


(5 votes, average: 4.80 out of 5)
Feeling fat?